143 related articles for article (PubMed ID: 26470903)
1. Salivary Gland Cancers: Biology and Systemic Therapy.
Goyal G; Mehdi SA; Ganti AK
Oncology (Williston Park); 2015 Oct; 29(10):773-80. PubMed ID: 26470903
[TBL] [Abstract][Full Text] [Related]
2. Aberrantly activated AREG-EGFR signaling is required for the growth and survival of CRTC1-MAML2 fusion-positive mucoepidermoid carcinoma cells.
Chen Z; Chen J; Gu Y; Hu C; Li JL; Lin S; Shen H; Cao C; Gao R; Li J; Ha PK; Kaye FJ; Griffin JD; Wu L
Oncogene; 2014 Jul; 33(29):3869-77. PubMed ID: 23975434
[TBL] [Abstract][Full Text] [Related]
3. Molecular signature of salivary gland tumors: potential use as diagnostic and prognostic marker.
Fonseca FP; Sena Filho M; Altemani A; Speight PM; Vargas PA
J Oral Pathol Med; 2016 Feb; 45(2):101-10. PubMed ID: 25990369
[TBL] [Abstract][Full Text] [Related]
4. MECT1-MAML2 fusion transcript defines a favorable subset of mucoepidermoid carcinoma.
Okabe M; Miyabe S; Nagatsuka H; Terada A; Hanai N; Yokoi M; Shimozato K; Eimoto T; Nakamura S; Nagai N; Hasegawa Y; Inagaki H
Clin Cancer Res; 2006 Jul; 12(13):3902-7. PubMed ID: 16818685
[TBL] [Abstract][Full Text] [Related]
5. Salivary Gland Neoplasms: Does Morphological Diversity Reflect Tumor Heterogeneity.
Rito M; Fonseca I
Pathobiology; 2018; 85(1-2):85-95. PubMed ID: 28930752
[TBL] [Abstract][Full Text] [Related]
6. Sustained expression of Mect1-Maml2 is essential for tumor cell growth in salivary gland cancers carrying the t(11;19) translocation.
Komiya T; Park Y; Modi S; Coxon AB; Oh H; Kaye FJ
Oncogene; 2006 Oct; 25(45):6128-32. PubMed ID: 16652146
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic and therapeutic implications of new molecular biomarkers in salivary gland cancers.
Stenman G; Persson F; Andersson MK
Oral Oncol; 2014 Aug; 50(8):683-90. PubMed ID: 24856188
[TBL] [Abstract][Full Text] [Related]
8. CRTC1/MAML2 fusion transcript in high grade mucoepidermoid carcinomas of salivary and thyroid glands and Warthin's tumors: implications for histogenesis and biologic behavior.
Tirado Y; Williams MD; Hanna EY; Kaye FJ; Batsakis JG; El-Naggar AK
Genes Chromosomes Cancer; 2007 Jul; 46(7):708-15. PubMed ID: 17437281
[TBL] [Abstract][Full Text] [Related]
9. An update on the systemic therapy of malignant salivary gland cancers: role of chemotherapy and molecular targeted agents.
Agulnik M; Siu LL
Curr Med Chem Anticancer Agents; 2004 Nov; 4(6):543-51. PubMed ID: 15579019
[TBL] [Abstract][Full Text] [Related]
10. [Mucoepidermoidcarcinoma - Importance in molecular pathology].
Nachtsheim L; Arolt C; Dreyer T; Meyer MF; Brobeil A; Gamerdinger U; Gattenlöhner S; Grosheva M; Wittekindt C; Klußmann JP
Laryngorhinootologie; 2020 Mar; 99(3):144-148. PubMed ID: 32120437
[TBL] [Abstract][Full Text] [Related]
11. [2009 update in salivary gland tumoral pathology].
Uro-Coste E
Ann Pathol; 2009 Sep; 29(4):274-85. PubMed ID: 19900633
[TBL] [Abstract][Full Text] [Related]
12. Salivary gland malignancies: the role for chemotherapy and molecular targeted agents.
Surakanti SG; Agulnik M
Semin Oncol; 2008 Jun; 35(3):309-19. PubMed ID: 18544445
[TBL] [Abstract][Full Text] [Related]
13. CRTC1-MAML2 and CRTC3-MAML2 fusions were not detected in metaplastic Warthin tumor and metaplastic pleomorphic adenoma of salivary glands.
Skálová A; Vanecek T; Simpson RH; Vazmitsel MA; Majewska H; Mukensnabl P; Hauer L; Andrle P; Hosticka L; Grossmann P; Michal M
Am J Surg Pathol; 2013 Nov; 37(11):1743-50. PubMed ID: 24121173
[TBL] [Abstract][Full Text] [Related]
14. t(11;19) translocation and CRTC1-MAML2 fusion oncogene in mucoepidermoid carcinoma.
O'Neill ID
Oral Oncol; 2009 Jan; 45(1):2-9. PubMed ID: 18486532
[TBL] [Abstract][Full Text] [Related]
15. Salivary gland cancers: current treatments, molecular characteristics and new therapies.
Chandana SR; Conley BA
Expert Rev Anticancer Ther; 2008 Apr; 8(4):645-52. PubMed ID: 18402531
[TBL] [Abstract][Full Text] [Related]
16. Systemic therapies for recurrent and/or metastatic salivary gland cancers.
Vattemi E; Graiff C; Sava T; Pedersini R; Caldara A; Mandarà M
Expert Rev Anticancer Ther; 2008 Mar; 8(3):393-402. PubMed ID: 18366287
[TBL] [Abstract][Full Text] [Related]
17. Recent advances in the treatment of salivary gland cancers: emphasis on molecular targeted therapy.
Milano A; Longo F; Basile M; Iaffaioli RV; Caponigro F
Oral Oncol; 2007 Sep; 43(8):729-34. PubMed ID: 17350323
[TBL] [Abstract][Full Text] [Related]
18. HER2 and EGFR gene copy number alterations are predominant in high-grade salivary mucoepidermoid carcinoma irrespective of MAML2 fusion status.
Nakano T; Yamamoto H; Hashimoto K; Tamiya S; Shiratsuchi H; Nakashima T; Nishiyama K; Higaki Y; Komune S; Oda Y
Histopathology; 2013 Sep; 63(3):378-92. PubMed ID: 23855785
[TBL] [Abstract][Full Text] [Related]
19. Oncocytic mucoepidermoid carcinoma of the parotid gland with CRTC1-MAML2 fusion transcript: report of a case with review of literature.
Fujimaki M; Fukumura Y; Saito T; Mitani K; Uchida S; Yokoyama J; Yao T; Ikeda K
Hum Pathol; 2011 Dec; 42(12):2052-5. PubMed ID: 21676434
[TBL] [Abstract][Full Text] [Related]
20. 11q21 rearrangement is a frequent and highly specific genetic alteration in mucoepidermoid carcinoma.
Clauditz TS; Gontarewicz A; Wang CJ; Münscher A; Laban S; Tsourlakis MC; Knecht R; Sauter G; Wilczak W
Diagn Mol Pathol; 2012 Sep; 21(3):134-7. PubMed ID: 22847156
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
